Trial: Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study.

Authors: Sacher F; Probst V;  Iesaka Y; Jacon P; Laborderie J; Mizon-Gérard F; Mabo P; Reuter S; Lamaison D; Takahashi Y; O'Neill MD; Garrigue S; Pierre B; Jaïs P; Pasquié JL; Hocini M; Salvador-Mazenq M; Nogami A; Amiel A; Defaye P; Bordachar P; Boveda S; Maury P; Klug D; Babuty D; Haïssaguerre M; Mansourati J; Clémenty J; Le Marec H.

Reference: Circulation. 2006 Nov 28;114(22):2317-24. Epub 2006 Nov 20.  PMID: 17116772

Purpose: To assess the outcome of ICD use in patients with Brugada Syndrone.

Number of Patients: 220

Number of Centers: 14

Design: Non-randomized, observational

Authors Conclusion: In this large Brugada syndrome population, a low incidence of arrhythmic events was found, with an annual event rate of 2.6% during a follow-up of >3 years, in addition to a significant risk of device-related complications (8.9%/year). Inappropriate shocks were 2.5 times more frequent than appropriate ones.

Key words:  ICD

Comment: It was not entirely apparent why the ICD complication rate was significantly higher than that observed in other studies.  While asymptomatic Brugada patients were at low risk, the overall annual event rate of 2.6% was not insubstantial relative to other device studies.


Summary written by Robert Kowal, MD, PhD